Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2019

Summarized financial information related to this collaboration is as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2019		2018		2019		2018
Alliance revenue	$	97	$	35	$	171	$	35

Cost of sales⁽¹⁾	23		1		74		1
Selling, general and administrative	19		2		38		2
Research and development ⁽²⁾	62		36		109		1,436

($ in millions)					June 30, 2019		December 31, 2018
Receivables from Eisai included in Other current assets					$	98	$	71
Payables to Eisai included in Accrued and other current liabilities ⁽³⁾					709		375
Payables to Eisai included in Other Noncurrent Liabilities ⁽³⁾					125		543

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Amount for the first six months of 2018 includes the upfront payment and future option payments.

⁽³⁾Includes accrued milestone and option payments.

Summarized financial information related to this collaboration is as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2019		2018		2019		2018
Alliance revenue	$	111	$	44	$	190	$	76

Cost of sales⁽¹⁾	73		24		92		36
Selling, general and administrative	33		9		59		16
Research and development	33		42		78		71

($ in millions)					June 30, 2019		December 31, 2018
Receivables from AstraZeneca included in Other current assets					$	105	$	52
Payables to AstraZeneca included in Accrued and other current liabilities⁽²⁾					605		405
Payables to AstraZeneca included in Other Noncurrent Liabilities⁽³⁾					300		250

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Includes accrued milestone and license option payments.

Summarized financial information related to this collaboration is as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2019		2018		2019		2018
Net product sales recorded by Merck	$	53	$	47	$	100	$	90
Merck’s profit share from sales in Bayer’s marketing territories	51		28		94		53
Total sales	104		75		194		143

Cost of sales⁽¹⁾	29		132		58		159
Selling, general and administrative	11		10		20		17
Research and development	32		28		62		56

($ in millions)					June 30, 2019		December 31, 2018
Receivables from Bayer included in Other current assets					$	41	$	32
Payables to Bayer included in Other Noncurrent Liabilities ⁽²⁾					375		375

⁽¹⁾Includes amortization of intangible assets.

⁽²⁾Represents accrued milestone payment.